ProHealth fibromyalgia Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

An Easy Way to Tell if You Have Small-Fiber Neuropathy? The Fibromyalgia Symptom Study

Small Nerves – Big, Big Problem? Drug Trial Points Finger at Autoimmunity in Fibromyalgia and ME/CFS

Twenty-Six Years of Hell: An ME/CFS/FM Recovery Story

What Makes You Forget?

12 Tips – Stick to Your Fibromyalgia Meal Plan

Motivation: It's Not What You Think

How to manage a relationship when you have a chronic illness

The Dos and Don’ts of Fibromyalgia

The Opioid Painkiller Clampdown – Will it Lead to Better Drugs?

That was Then…This is Now Life with Fibromyalgia

 
Print Page
Email Article

Half of CFS patients with high HHV-6 & EBV titers improve 30% or better on Valcyte: Montoya

  [ 10 votes ]   [ 1 Comment ]
www.ProHealth.com • October 16, 2012


Article:
Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers
- Source: Journal of Medical Virology, Oct 10, 2012

By Tessa Watt, Jose G Montoya, et al.

[Note: Dr. Montoya has studied the impact of the antiviral valganciclovir (Valcyte®) on ME/CFS patients affected by these viruses for years. This report suggests longer term treatment may be linked to better response.]

Abstract:
Valganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV-6) and Epstein–Barr virus (EBV) IgG antibody titers [concentrations].

This study investigated whether antibody titers against HHV-6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients.

An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900mg valganciclovir daily (55 of whom took an induction dose of 1,800mg daily for the first 3 weeks).

Antibody titers were considered high if:

• HHV-6 IgG was 1:320 or greater,

• EBV viral capsid antigen (VCA) IgG was 1:640 or greater,

• And EBV early antigen (EA) IgG was 1:160 or greater.

Patients self-rated physical and cognitive functioning as a percentage of their functioning prior to illness.

Patients were categorized as responders if they experienced at least 30% improvement in physical and/or cognitive functioning.

Thirty-two patients (52%) were categorized as responders.

Among these:

• 19 patients (59%) responded physically

• And 26 patients (81%) responded cognitively.

Baseline antibody titers showed no significant association with response.

After treatment, the average change in physical and cognitive functioning levels for all patients was +19% and +23%, respectively (P<0.0001). Longer treatment was associated with improved response (P=0.0002).

No significant difference was found between responders and non-responders among other variables analyzed.

Valganciclovir treatment, independent of the baseline antibody titers, was associated with self-rated improvement in physical and cognitive functioning for CFS patients who had positive HHV-6 and/or EBV serologies.

Longer valganciclovir treatment correlated with an improved response.

Source: Journal of Medical Virology, Oct 10, 2012;84(12), pp 1967-1974. DOI: 10.1002/jmv.23411, by Watt T, Oberfoell S, Balise R, Lunn MR, Kar AK, Merrihew L, Bhangoo MS, Montoya JG. Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University Medical Center, Palo Alto, California; University of Michigan Medical School, Ann Arbor; David Geffen School of Medicine, UCLA, Los Angeles, California; Brigham and Women’s Hospital, Boston, Massachusetts; San Diego School of Medicine, University of California, USA. [Email: Jose G Montoya Gilberto@stanford.edu]





Post a Comment

Featured Products From the ProHealth Store
Guaifenesin FA™ Hydroxocobalamin Extreme™ FibroSleep™


Article Comments Post a Comment

Longer valganciclovir treatment correlated with an improved response.
Posted by: IanH
Oct 16, 2012
It would have been great if this improved response over longer term treatment could have been enumerated.
Reply Reply
 
Optimized Curcumin Longvida with Omega-3

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Fibro Freedom™ Fibro Freedom™
Soothes, Strengthens & Revitalizes
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth

Natural Remedies

How One Tiny Molecule Turned into One Huge Health Breakthrough How One Tiny Molecule Turned into One Huge Health Breakthrough
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage
Can Pomegranates Slow Aging? Can Pomegranates Slow Aging?
The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map